Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
Related Posts
Sibanye-Stillwater Cuts Guidance, Swings to Wider-Than-Expected Net Loss
Sibanye-Stillwater cut its gold production guidance for the year and posted a swing to a wider net loss than analysts had expected for the half […]
Carlsberg to Buy Britvic for $4.2 Billion
The Danish brewer agreed to buy London-listed soft drinks maker Britvic as part of a plan to expand in the non-alcoholic beverage market and reduce […]
China Allows Robotaxis Without Operators in Shanghai
China has added Shanghai to a list of cities allowing the use of driverless robotaxis in which no safety supervisors are present, part of efforts […]